Botulinum toxin in urology. An inventory;Botulinumtoxin in der urologie. Eine bestandsaufnahme

Urologe - Ausgabe A

Volumn 43, Issue 8, 2004, Pages 963-975

  Schulte Baukloh, H ^a,b   Knispel, H H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b St Hedwig Kliniken   (Germany)

Author keywords

Botox; Botulinum toxin; Detrusor sphincter dyssynergia; Dysport; Neurogenic detrusor hyperactivity; Voiding disorders

Indexed keywords

BOTULINUM TOXIN;

BLADDER SPHINCTER; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DRUG APPROVAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MICTURITION DISORDER; MUSCLE CONTRACTION; NEUROGENIC BLADDER; PELVIS PAIN SYNDROME; RESIDUAL URINE; REVIEW; TREATMENT INDICATION;

BOTULINUM TOXINS; CHOLINERGIC ANTAGONISTS; HUMANS; MUSCLE HYPERTONIA; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY TRACT; URINATION DISORDERS; UROLOGIC DISEASES; UROLOGY;

EID: 4544352827     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0635-1     Document Type: Review

References (74)

1. Aoki R (1998) The development of BOTOX® - its history and pharmacology. Pain Digest 8: 337-341
2. Aoki R (2001) Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248 (Suppl 1): 3-10
3. Aoki R, Francis J, Reynolds H, Leumer D (2003) Comparison of the therapeutic window of different botulinum neurotoxin preparations in an animal model. Am Acad Neurol 60(5Suppl 1): A212-213
4. Barton CH, Khonsari F, Vaziri ND, Byrne C, Gordon S, Friis R (1986) The effect of modified transurethral sphincterotomy on autonomic dysreflexia. J Urol 135/1: 83-85
5. Borodic GE, Ferrante RJ, Perace LB, Alderson K (1994) Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J, Hallet M (eds) Therapy with botulinum toxin. Dekker, New York, pp 119-157
6. Borodic GE, Ferrante R, Pearce LB, Smith K (1994) Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 9/1: 31-39
7. Borodic GE, Pearce LB, Smith KL, Phelan M, Ferrante R (1993) Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthal Plast Reconstr Surg 9/3: 182-190
8. Brin MF (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve (Suppl 6): S146-168
9. Brin MF, Lew MF, Adler CH et al. (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53/7: 1431-1438
10. Brass S, Braun PM, Seif C et al. (2002) Botulinum-A-Toxin bei therapierefraktärer neurogener und nicht-neurogener Detrusorhyperaktivität. Urologe B 42: 428-429
11. Burgen A, Dickens F, Zatman LJ (1949) The action of botulinum toxin on the neuromuscular junction. J Physiol 109: 10-24
12. Carl S, Forth H, Breul J (2003) Botulinum-A-Toxin (Dysport®) zur Behandlung von Patienten mit interstitieller Cystitis. Urologe A 42 (Suppl 1): S49
13. Chancellor M, O'Leary M, Erickson J et al. (2003) Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 169 (Suppl 4): 351
14. Cheshire WP, Abashian SW, Mann JD (1994) Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59/1: 65-69
15. Davis LE (1993) Botulinum toxin: from poison to medicine. West J Med 158: 25-29
16. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139/5: 919-922
17. Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71/1: 24-26
18. Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79/6: 715-717
19. Grosse J, Kramer G, Schurch B, Stöhrer M (2002) Repeat detrusor injections of botulinum A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolerance. Neurourol Urodyn 21/4: 386-387
20. Grosse J, Kramer G, Stöhrer M (2003) Erlaubt die Urodynamik eine Vorhersage des Erfolges einer Botulinum-Toxin-A-(BTX-A-)Reinjektion bei schwerer neurogener Detrusorhyperaktivität (nDÜ)? Urologe A 42 (Suppl 1): 49
21. Grosse J, Löchner-Ernst D, Kramer G, Stöhrer M (2003) Erfahrungen mit Dysport® einem Botulinum-Toxin-A-(BTX-A-)Präparat, zur Behandlung ausgeprägter, neurogener Detrusorhyperaktivität (nDÜ). Urologe A 42 (Suppl 1): 59
22. Haferkamp A, Krengel U, Reitz A et al. (2003) Lack of ultrastructural detrusor changes due to botulinum-A toxin injections in patients with hyperreflexic neurogenic bladder dysfunction. Urologe A 42 (Suppl 1): 59
23. Hampel C, Pahernik S, Gillitzer R, Hohenfellner M, Jhüroff JW (2003) Erste klinische Erfahrungen mit der disseminierten Botulinumtoxin-A- Detrusorinjektion bei nicht-neurogener therapierefraktärer Blasenhyperaktivität. Urologe A 42 (Suppl 1): 50
24. Harper M, Popat RB, Dasgupta R, Fowler G, Dasgupta P (2003) A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92/3: 325-326
25. Hernandez RD, Hurwitz RS, Foote JE (1994) Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 152 (5 Pt 1): 1582-1585
26. Jankovic J, Brin MF (1997) Botulinum toxin: historical perspective and potential new indications. Muscle Nerve (Suppl 6): 129-145
27. Jankovic J, Schwartz K, Donovan DT (1990) Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 53/8: 633-639
28. Kerner J (1822) Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Cotta, Stuttgart
29. Kuo HC (2003) Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61/3: 550-554
30. Kuo HC (2003) Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 170/5: 1908-1912
31. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE (1987) Distant effects of local injection of botulinum toxin. Muscle Nerve 10/6: 552-555
32. Lange DJ, Rubin M, Greene PE et al. (1991) Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 14/7: 672-675
33. Loch A, Loch T, Osterhage J, Alloussi S, Stöckle M (2003) Botulinum-A toxin detrusor injections in the treatment of non- neurologic and neurologic cases of urge incontinence. Eur Urol 2/1: 172
34. Mall V, Glocker FX, Frankenschmidt A et al. (2001) Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele. Pediatr Nephrol 16/12: 1161-1162
35. Maria G, Destito A, Lacquaniti S, Bentivoglio AR, Brisinda G, Albanese A (1998) Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 22;352 (9128): 625
36. Meunier FA, Schiavo G, Molgo J (2002) Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 96 (1-2): 105-113
37. Naumann M (2003) Botulinumtoxin - Grundlagen. In: Naumann M (Hrsg) Botulinumtoxin: Wirkprinzip und klinische Anwendung. UNI-MED Verlag, Bremen, S 10-17
38. Naumann M, Toyka KV, Moore P (2003) History and current applications of botulinum toxin - from poison to remedy. In: Handbook of botulinum toxin treatment. Blackwell Science, Oxford, pp 3-8
39. Paiva A de, Meunier FA, Molgo J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parents terminals. Proc Natl Acad Sci 96: 3200-3205
40. Petit H, Wiart L, Gaujard E et al. (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36/2: 91-94
41. Phelan MW, Franks M, Somogyi GT et al. (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165/4: 1107-1110
42. Reichel G (2002) Spastik. In: Therapieleitfaden Spastik - Dystonien. UNI-MED, Bremen, S 33-40
43. Reitz A, von Tobel J, Stöhrer M et al. (2002) European experience of 184 cases treated with botulinum-a toxin injections into the detrusor muscle for neurogenic incontinence. Neurourol Urodyn 21/4: 427-428
44. Richter R, Schaaf V (2002) Botulinum-A-Toxin zur Behandlung der Reflexinkontinenz bei neurogener Blasenstörung. Aktuel Urol 33/2: 141-142
45. Schantz E, Johnson EA (1997) Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 40/3: 317-327
46. Schulte-Baukloh H, Michael T, Miller K, Knispel HH (2002) Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU Int 90/7: 716-720
47. Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH (2002) Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59/3: 325-328
48. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH (2003) Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44/1: 139-143
49. Schulte-Baukloh H, Schobert J, Weiss C, Stürzebecher B, Knispel HH (2003) Botulinumtoxin-A als Alternative in der Behandlung hyperaktiver Blasenfunktionsstörungen: Wie denken eigentlich die Patienten über diese Therapie? Urologe A 42 (Suppl 1): 50
50. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155/3: 1023-1029
51. Schurch B, Hodler J, Rodic B (1997) Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 63/4: 474-476
52. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692-697
53. Schurch B, Tenti G, Reitz A (2002) Electromotive drug administration of lidocaine to anesthetize the bladder before botulinumtoxin-A injections into the detrusor. Eur Urol 1 (Suppl 1): 146
54. Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79: 734-770
55. Scott AB, Rosenbaum A, Collins CC (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12/12: 924-927
56. de Seze M, Petit H, Gallien P et al.(2002) Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42/1: 56-62
57. Shaari CM, George E, Wu BL, Biller HF, Sanders I (1991) Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 101/9: 960-964
58. Shaari CM, Sanders I (1993) Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 16: 964-969
59. Shapiro E, Seller MJ, Lepor H et al.(1998) Altered smooth muscle development and innervation in the lower genitourinary and gastrointestinal tract of the male human fetus with myelomeningocele. J Urol 160 (3 Pt 2): 1047-1053;discussion 1079
60. Siatkowski RM, Tyutyunikov A, Biglan AW et al. (1993) Serum antibody production to botulinum A toxin. Ophthalmology 100/12: 1861-1866
61. Sloop RR, Cole BA, Escutin RO (1997) Human response to botulinum toxin injection: type B compared with type A. Neurology 49/1: 189-194
62. Smith CP, Chancellor MB, Degroat WC, Boone TB, Somogyi GT (2003) Botulinum toxin: a new twist on "A" vs "D". J Urol 169 (Suppl 4): 38
63. Smith CP, Fraser MO, Bartho L, Degroat WC, Chancellor MB, Somogyi GT (2002) Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions. J Urol 167 (Suppl 4): 41
64. Smith CP, O'Leary M, Erickson J, Somogyi GT, Chancellor MB (2002) Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct 13/3: 185-186
65. Steinhardt GF, Naseer S, Cruz OA (1997) Botulinum toxin: novel treatment for dramatic urethral dilatation associated with dysfunctional voiding. J Urol 158/1: 190-191
66. Stöhrer M, Schurch B, Kramer G, Schmid D, Gaul G, Hauri D (1999) Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: A new alternative to medical and surgical procedures? Neurourol Urodyn 18: 401-402
67. Swierzewski SJ 3rd, Gormley EA, Belville WD, Sweetser PM, Wan J, McGuire EJ (1994) The effect of terazosin on bladder function in the spinal cord injured patient. J Urol 151/4: 951-954
68. Van Ermengem E (1897) Über einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infekt 26: 1-56
69. Wheeler JS Jr., Walter JS, Chintam RS, Rao S (1998) Botulinum toxin injections for voiding dysfunction following SCI. J Spinal Cord Med 21/3: 227-229
70. Williams RS, Tse CK, Dolly JO, Hambleton P, Melling J (1983) Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes. Eur J Biochem 131/2: 437-445
71. Wyndaele JJ, Van Dromme SA (2002) Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40/11: 599-600
72. Yoshimura N, Chancellor MB (2002) Current and future pharmacological treatment for overactive bladder. J Urol 168/5: 1897-1913
73. Zermann DH, Ishigooka M, Doggweiler-Wiygul R, Schubert J, Schmidt RA (2001) The male chronic pelvic pain syndrome. World J Urol 19/3: 173-179
74. Zermann D, Ishigooka M, Schubert J, Schmidt RA (2000) Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 38/4: 393-399